The UK may be Europe’s pre-eminent biotech sector but its potential has been held back by a huge shortfall in cash compared with the US. That could be about to change, with the launch this week of a long-awaited scheme to entice pension funds to invest in early-stage biopharma companies.
Key Takeaways
-
The UK is Europe’s biggest biotech sector, but still struggles to attract enough capital
-
In 2022, UK biotechs raised £1.8bn ($2bn) – dwarfed by the $51bn raised by US biotech firms
The UK-based global asset manager ICG has been selected by the government’s British Business Bank to receive £100m investment from its Long-term Investment for Technology and Science (LIFTS) initiative